Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 8/20 | 0.44 |
| ▸ | PLD1 | Q13393 | 7/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.40 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871702 | 0.91 | PLD2 (0.46) | PLD2PLD1OPRM1OPRD1OPRK1 | |
| SCHEMBL5871280 | 0.90 | PLD2 (0.49) | PLD2PLD1CACNA1GACSS2 | |
| SCHEMBL5204133 | 0.85 | HTR2A (0.49) | PLD2PLD1CACNA1GDRD4 | |
| SCHEMBL6619900 | 0.84 | HTR1A (0.48) | PLD2PLD1OPRM1OPRD1OPRK1 | |
| SCHEMBL5871261 | 0.84 | KDM4E (0.44) | OPRM1CACNA1G | |
| SCHEMBL5871623 | 0.82 | KMT2A (0.41) | OPRM1OPRD1OPRK1CACNA1GDRD4 | |
| SCHEMBL5871557 | 0.82 | KMT2A (0.41) | OPRM1OPRD1OPRK1CACNA1GDRD4 | |
| SCHEMBL5871851 | 0.80 | HTR2A (0.58) | PLD2PLD1 | |
| SCHEMBL5202479 | 0.76 | HTR2A (0.47) | PLD2PLD1CACNA1GDRD4 | |
| SCHEMBL5871535 | 0.75 | PLD2 (0.50) | PLD2PLD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | claimed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | claimed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | claimed |
| EP-1179532-B1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | EISAI R&D MAN CO LTD (JP) | 2007-06-13 | — | — | EP | disclosed |
| US-7071201-B2 | Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline | EISAI CO., LTD. (JP) | 2006-07-04 | — | — | US | disclosed |
| EP-0976732-B1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2004-11-24 | — | — | EP | disclosed |
| US-6579881-B2 | Indoles | EISAI CO., LTD. (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6573384-B1 | 1,4-substituted cyclic amine compound which is useful as a pharmaceutical, and an intermediate for the process | EISAI CO., LTD. (JP) | 2003-06-03 | — | — | US | disclosed |
| US-6448243-B1 | SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA | EISAI CO., LTD. (JP) | 2002-09-10 | — | — | US | disclosed |
| US-20020086999-A1 | Certain quinoline derivatives | EISAI CO., LTD. | 2002-07-04 | — | — | US | disclosed |
| US-20020019531-A1 | Indoles | EISAI CO., LTD. | 2002-02-14 | — | — | US | disclosed |
| EP-1179532-A1 | PROCESS FOR THE PRODUCTION OF INDOLE DERIVATIVES AND INTERMEDIATES THEREFOR | Eisai Co., Ltd. (JP) | 2002-02-13 | — | — | EP | disclosed |
| JP-2000355591-A | PRODUCTION OF INDOLE DERIVATIVE AND ITS INTERMEDIATE | EISAI CO LTD | 2000-12-26 | — | — | JP | disclosed |
| EP-0976732-A1 | 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019531-A1 | Indoles | INMT, MUSK, MB | PLD2 1692/4885PLD1 1271/4885OPRM1 471/4885 |
| US-20020086999-A1 | Certain quinoline derivatives | CHRM1, CHRNA5, CHRNA4 | PLD2 1674/4885PLD1 1415/4885OPRM1 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.